Comparison of two immunotoxins against DLL3 receptor; as an inhibitor for small cell lung cancer [PDF]
Despite the efforts of researchers to develop new treatments for small cell lung cancer (SCLC), achieving effective treatment has not yet happened. Targeted therapy utilizing delta-like ligand 3 (DLL3), which is highly expressed in SCLC patients, holds ...
Mohammad Hossein Ataee +4 more
doaj +2 more sources
Integrated bioprocessing and genetic strategies to enhance soluble expression of anti-HER2 immunotoxin in E. Coli [PDF]
Immunotoxins are widely applied for cancer therapy. However, bacterial expression of immunotoxins usually leads to the formation of insoluble and non-functional recombinant proteins. This study was aimed to improve soluble expression of a novel anti-HER2
Sheida Mani +3 more
doaj +2 more sources
Unlocking the potential of engineered microbes in immunotoxin-based cancer therapy [PDF]
Immunotoxins (ITs), as targeted cancer therapies, confront limitations including off-target effects, immunogenicity, and inadequate tumor penetration, hindering clinical translation.
Quan Wang +10 more
doaj +2 more sources
Production and Verification of Anti-Tumor Activity of Monoclonal Anti-EGFR-Recombinant PE38 Immunotoxin in A431 Tumor Cells [PDF]
Background: Tumor growth and progression depend largely on the activity of cell membrane receptors like epidermal growth factor receptor (EGFR). This receptor plays a significant role in the growth and survival of many solid tumors.
Khalil Hajiasgharzadeh +2 more
doaj +1 more source
In vivo solid tumor targeting with recombinant VEGF-diphtheria immunotoxin [PDF]
Objective(s): A variety of signaling molecules have been identified that play a role in angiogenesis, of prime importance, vascular endothelial growth factor (VEGF) and its resceptor (VEGFR), which is highly expressed in most human solid tumors ...
Mohammad Hosseininejad-Chafi +9 more
doaj +1 more source
Ebola virus (EBOV), a member of the mononegaviral family Filoviridae, causes severe disease associated with high lethality in humans. Despite enormous progress in development of EBOV medical countermeasures, no anti-EBOV treatment has been approved.
Yingyun Cai +5 more
doaj +1 more source
The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy. [PDF]
BackgroundTumor microenvironments present significant barriers to penetration by antibodies and immunoconjugates. Tumor microenvironments, however, are difficult to study in vitro.
Broaddus, V Courtney +8 more
core +6 more sources
Immunotoxins consist of an antibody or antibody fragment that binds to a specific cell surface structure and a cytotoxic domain that kills the cell after cytosolic uptake. Pseudomonas Exotoxin A (PE) based immunotoxins directed against a variety of tumor
Anie P. Masilamani +25 more
doaj +1 more source
Targeted delivery of immunotoxin by antibody to ganglioside GD3: a novel drug delivery route for tumor cells. [PDF]
Gangliosides are sialic acid-containing glycolipids expressed on plasma membranes from nearly all vertebrate cells. The expression of ganglioside GD3, which plays essential roles in normal brain development, decreases in adults but is up regulated in ...
Vanina Torres Demichelis +4 more
doaj +1 more source
GUCY2C lysosomotropic endocytosis delivers immunotoxin therapy to metastatic colorectal cancer. [PDF]
The emergence of targeted cancer therapy has been limited by the paucity of determinants which are tumor-specific and generally associated with disease, and have cell dynamics which effectively deploy cytotoxic payloads.
Berman-Booty, Lisa D +5 more
core +6 more sources

